Developing and validating COVID-19 adverse outcome risk prediction models from a bi-national European cohort of 5594 patients

Author:

Jimenez-Solem Espen,Petersen Tonny S.,Hansen Casper,Hansen Christian,Lioma Christina,Igel Christian,Boomsma Wouter,Krause Oswin,Lorenzen Stephan,Selvan Raghavendra,Petersen Janne,Nyeland Martin Erik,Ankarfeldt Mikkel Zöllner,Virenfeldt Gert Mehl,Winther-Jensen Matilde,Linneberg Allan,Ghazi Mostafa Mehdipour,Detlefsen Nicki,Lauritzen Andreas David,Smith Abraham George,de Bruijne Marleen,Ibragimov Bulat,Petersen Jens,Lillholm Martin,Middleton Jon,Mogensen Stine Hasling,Thorsen-Meyer Hans-Christian,Perner Anders,Helleberg Marie,Kaas-Hansen Benjamin Skov,Bonde Mikkel,Bonde Alexander,Pai Akshay,Nielsen Mads,Sillesen Martin

Abstract

AbstractPatients with severe COVID-19 have overwhelmed healthcare systems worldwide. We hypothesized that machine learning (ML) models could be used to predict risks at different stages of management and thereby provide insights into drivers and prognostic markers of disease progression and death. From a cohort of approx. 2.6 million citizens in Denmark, SARS-CoV-2 PCR tests were performed on subjects suspected for COVID-19 disease; 3944 cases had at least one positive test and were subjected to further analysis. SARS-CoV-2 positive cases from the United Kingdom Biobank was used for external validation. The ML models predicted the risk of death (Receiver Operation Characteristics—Area Under the Curve, ROC-AUC) of 0.906 at diagnosis, 0.818, at hospital admission and 0.721 at Intensive Care Unit (ICU) admission. Similar metrics were achieved for predicted risks of hospital and ICU admission and use of mechanical ventilation. Common risk factors, included age, body mass index and hypertension, although the top risk features shifted towards markers of shock and organ dysfunction in ICU patients. The external validation indicated fair predictive performance for mortality prediction, but suboptimal performance for predicting ICU admission. ML may be used to identify drivers of progression to more severe disease and for prognostication patients in patients with COVID-19. We provide access to an online risk calculator based on these findings.

Funder

Novo Nordisk Fonden

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3